Director/PDMR Shareholding

RNS Number : 3397D

Renalytix PLC

28 June 2021

 

Renalytix plc 

("Renalytix" or the "Company")

Director/PDMR Dealing

The Company had been informed today that Christopher Mills, a non-executive director and interim Chairman, completed the sale of 6,100 ordinary shares of 0.25 pence each ("Ordinary Shares") in the Company at a price of £11.25 per share.

Following completion of the sale, Christopher Mills is interested in 9,174,401 Ordinary Shares representing 12.71% of the issued share capital of the Company as enlarged by the recent option exercise.

For further information, please contact:  

Renalytix plc		www.renalytix.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone]  or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.¹ Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

¹   https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About KidneyIntelX

KidneyIntelX, is a first-of-kind, bioprognostic^TM platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com ). For more information, visit www.renalytix.com .

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Harwood Capital LLP and Harwood Capital Management (Gibraltar) Limited
2	Reason for the notification
a)	Position/status	Christopher Mills, the issuer's interim chairman, is Chief Executive Officer of Harwood
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Renalytix AI plc
b)	LEI	213800NTOH3FK3WER551
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of  £0.0025 each
	Identification code	GB00BYWL4Y04
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			£11.25	6,100
d)	Aggregated information
	- Aggregated volume	6,100
	- Price	£68,625.00
e)	Date of the transaction	25 June 2021
f)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHEAEKPALKFEFA